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Abstract: The purpose of this study is to determine if a preventive treatment with curcumin can
protect intestinal epithelial cells from inflammatory damage induced by IFNγ. To achieve this goal
we have used a human intestinal epithelial cell line (HT29) treated with IFNγ to undergo apoptotic
changes that can reproduce the damage of intestinal epithelia exposed to inflammatory cytokines.
In this model, we measured the effect of curcumin (curcuminoid from Curcuma Longa) added as a
pre-treatment at different time intervals before stimulation with IFNγ. Curcumin administration
to HT29 culture before the inflammatory stimulus IFNγ reduced the cell apoptosis rate. This effect
gradually declined with the reduction of the curcumin pre-incubation time. This anti-apoptotic
action by curcumin pre-treatment was paralleled by a reduction of secreted IL7 in the HT29 culture
media, while there was no relevant change in the other cytokine levels. Even though curcumin
pre-administration did not impact the activation of the NF-κB pathway, a slight effect on the
phosphorylation of proteins in this inflammatory signaling pathway was observed. In conclusion,
curcumin pre-treatment can protect intestinal cells from inflammatory damage. These results can be
the basis for studying the preventive role of curcumin in inflammatory bowel diseases.
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1. Introduction
Chronic inflammation in inflammatory bowel disease (IBD) results from an inappropriate response
to intestinal microbes in a genetically-susceptible host [1].
The incidence of IBD is increasing worldwide, and this increase seems to be more rapid in areas of
the world that are experiencing a rapid socioeconomic transformation, particularly from low-income,
rural to high-income, urbanized countries [2]. This epidemiological data, together with the observation
that children of immigrants moving from countries with a low incidence of IBD to countries with
high incidence have the same risk of developing IBD as the population of the country of immigration,
indicate that environmental factors may play a major role in determining the risk of the disease [3].
Among the environmental factors, the role of diet gained a large amount of attention, and various
substances in food have been found to influence the composition of gut microbiota, as well as the
mucosal permeability and immune function within the gut [4]. Restrictive diets have a therapeutic role
in pediatric Crohn’s disease (CD). Exclusive enteral nutrition (EEN) with elemental and semi-elemental
formulas are the most widely studied restrictive diet which, in clinical trials in children with CD,
proved to reduce clinical disease activity and improve mucosal inflammation [5].
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The role of dietary supplements known for their anti-inflammatory properties such as vitamin D,
soluble fibers, and long chain fatty acid have also been investigated both in animal models and clinical
studies, and some evidence exists to suggest a potential protective role against the development or
progression of gut inflammation [6].
Preventive dietary intervention may be critical, particularly in children, considered that there is a
trend toward an earlier onset of IBD in Western countries.
Curcuma Longa, also known as turmeric, is a perennial plant of the ginger family widely cultivated
in Southern Asia. The root powder of Curcuma Longa is widely used for culinary purposes and in
traditional medicine, mostly in Asia. The best-studied component of this plant is curcumin, which
usually represents about 3% of turmeric powder. Curcumin has several pharmacological properties,
including anti-inflammatory, anti-microbial, and anti-tumorigenic activities which seem all to be related
to the ability of curcumin to modulate the expression of molecules involved in the inflammatory cascade
and programmed cell death [7,8]. The role of curcumin in IBD has been investigated in two small,
randomized, placebo-controlled trials where curcumin was given in association with a 5-aminosalicylic
acid (5-ASA) compound to induce and maintain remission in patients with mild to moderate ulcerative
colitis (UC). In both studies, the association of curcumin to 5-ASA was superior to the 5-ASA alone in
inducing and maintaining clinical and endoscopic remission [9,10].
The effects of curcumin in gut inflammation has been studied both in mouse and human models
providing a rationale for the possible beneficial role of curcumin use in IBD.
Preclinical studies in cellular and animal models showed that curcumin can modulate the
inflammatory cytokine cascade and the vascular adhesion molecule expression and inhibit the nuclear
factor-kappa B (NF-κB) [11]. Recently Midura-Kiela et al. found that, in human and mouse colonocytes,
curcumin reduces the expression of IFNγ, one of the most prominent proinflammatory cytokines
which drives a cascade of events that are thought to contribute to the pathogenesis of IBD [12].
In mouse models of colitis induced by chemicals, curcumin administration before the chemical
insult exerted a protective effect limiting the histopathological damage and the activation of the
inflammatory cascade [13–15].
In this study, we investigated the effect of curcumin pre-administration on human intestinal cells
exposed to IFNγ as a proinflammatory insult.
We used the human colorectal adenocarcinoma cell line HT29. HT29 is a model of intestinal
epithelium susceptible to the damage induced by inflammatory cytokines, such as IFNγ and
TNFα which represent a suitable in vitro model to study the effect of inflammation on intestinal
epithelia [16,17].
Increased apoptosis of epithelial cells is a well-known pathological feature in IBD. In particular,
colonic biopsies of subjects with UC typically show increased apoptosis in crypt epithelial cells [18,19];
an increased enterocyte apoptosis is a common finding also in CD [20]. Of note, anti-inflammatory
treatments also downregulate epithelial apoptosis [21]. This is particularly important if we consider that
epithelial cell apoptosis can lead to barrier dysfunction and amplification of disease. Taken together,
these data highlight the role of epithelial cells apoptosis in IBD.
It is commonly assumed that curcumin exerts its action through antioxidant and anti-apoptotic
effects [22–24]. However, other authors recently claimed that chemical properties of curcumin could
have interfered with in vitro experiments in most studies, raising doubts on the beneficial effect of this
substance [25]. To obtain more robust data, we analyzed the anti-apoptotic properties of curcumin by
exploiting different methods including label-free measures.
The primary aim of this study was to investigate whether pre-treatment with curcumin can
prevent the development of apoptosis in HT29 cells treated with IFNγ. Apoptosis and cell death
were measured by classical methods, such as flow cytometry, MTT assay, but also by more innovative
label-free instrumentation measuring the change in impedance due to the adherent cells on the surface
of the plate well.
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In addition, we assessed if the action of curcumin on IFNγ-induced apoptosis is associated with a
modulation of NF-κB signaling and inflammatory cytokine production [8,26,27].
We showed that pretreatment with curcumin 24 h before the administration of IFNγ can
downregulate apoptosis in intestinal epithelial cells. Further studies will address whether curcumin
anti-apoptotic properties may have a possible role in IBD prevention and treatment.
2. Materials and Methods
2.1. Cell Culture and Experimental Design
HT29 cells (human colorectal adenocarcinoma cell line), obtained from Sigma Aldrich (Sigma
Aldrich, St. Louis, MO, USA) were cultured in Roswell Park Memorial Institute medium (RPMI)
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and
0.1 mg/mL streptomycin (all from EuroClone, Milano, Italy). HT29 cells were seeded in different well
plates, depending on the experimental needs, at a density of about 80,000–90,000/cm2.
Forty-eight hours after seeding, cells were stimulated with 100 U/mL IFNγ (Interferon Gamma 1b,
Imukin, Boehringer Ingelheim, Milano, Italy) as inflammatory stimulus. To investigate the protective
effect of curcumin, HT29 cells were pre-incubated with 1 µM curcumin (derived from Curcuma Longa,
Sigma Aldrich) at different time intervals: 24, 12, 6, 4, 2, or 0 h before the IFNγ treatment.
Curcumin alone, without any inflammatory stimulus, was also added to the cells to evaluate the
effect on cell status. At 96 h of culture, after 48 h from the addition of IFNγ, cells were harvested for
analysis. The experimental design is reproduced graphically in Figure 1. Curcumin was dissolved
and solubilized in 100% ethanol (Sigma Aldrich). The final concentration of the vehicle in the cultured
media did not exceed 0.01% (v/v).
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Figure 1. Representative illustration of the experimental design. Forty-eight hours after seeding, HT29 
cells were stimulated with 100 U/mL IFNγ as inflammatory stimulus. To investigate the protective 
effect of curcumin, cells were pre-incubated with 1 µM curcumin (derived from Curcuma Longa) at 
different time points: 24, 12, 6, 4, 2, or 0 h before the IFNγ treatment. At 96 h of culture (48 h after the 
addition of IFNγ) cells were harvested for analysis. 
2.2. Programmed Cell Death Assay 
The apoptosis rate of HT29 was analyzed by flow cytometry using FITC-conjugated Annexin V 
(An) and propidium iodide staining (Annexin V-FITC Apoptosis Detection Kit, Immunostep, 
Salamanca, Spain), according to the producer’s instructions. HT29 cells were seeded in a 24-well plate 
at an initial concentration of 1.8 × 105 per well. Forty-eight hours after IFNγ treatment, cells were 
harvested from the culture plate using 0.05% Trypsin-EDTA solution (EuroClone), washed with 
phosphate-buffered saline, and resuspended in the provided staining buffer for the incubation with 
Annexin V and propidium iodide. Flow cytometry analysis was performed on a BD FACSCalibur 
cytometer (Becton Dickinson, NJ, USA), and data were then analyzed with FlowJo software (version 
7.6, Treestar, Inc., Ashland, OR, USA). The apoptotic cells (Annexin V positive, An+) were 
characterized based on the fluorescence emitted. Results were obtained by three independent 
experiments, performed in duplicate, and expressed as the fold increase after normalization on 
untreated controls. 
Figure 1. Representative illustration of the experimental design. Forty-eight hours after seeding,
HT29 cells were stimulated with 100 U/mL IFNγ as inflammatory stimulus. To investigate the protective
effect of curcumin, cells were pre-incubated with 1 µM curcumin (derived from Curcuma Longa) at
different time points: 24, 12, 6, 4, 2, or 0 h before the IFNγ treatment. At 96 h of culture (48 h after the
addition of IFNγ) cells were harvested for analysis.
2.2. Programmed Cell Death Assay
The apoptosis rate of HT29 was analyzed by flow cytometry using FITC-conjugated Annexin
V (An) and propidium iodide staining (Annexin V-FITC Apoptosis Detection Kit, Immunostep,
Salamanca, Spain), according to the producer’s instructions. HT29 cells were seeded in a 24-well
plate at an initial concentration of 1.8 × 105 per well. Forty-eight hours after IFNγ treatment, cells
were harvested from the culture plate using 0.05% Trypsin-EDTA solution (EuroClone), washed with
phosphate-buffered saline, and resuspended in the provided staining buffer for the incubation with
Annexin V and propidium iodide. Flow cytometry analysis was performed on a BD FACSCalibur
cytometer (Becton Dickinson, NJ, USA), and data were then analyzed with FlowJo software (version 7.6,
Treestar, Inc., Ashland, OR, USA). The apoptotic cells (Annexin V positive, An+) were characterized
based on the fluorescence emitted. Results were obtained by three independent experiments, performed
in duplicate, and expressed as the fold increase after normalization on untreated controls.
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2.3. Cell Viability Assay
Cytotoxicity was evaluated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; Sigma Aldrich) colorimetric assay. Briefly, 2.5 × 104 HT29 cells per well were seeded
in a 96-well plate, pre-treated or not with curcumin for 24 h and stimulated with IFNγ at 48 h of
culture. Ninety-six hours after seeding the MTT solution (5 mg/mL) was added to cell culture.
The tetrazolium dye was reduced by metabolically-viable cells in purple formazan. After four hours
of incubation at 37 ◦C, dimethyl sulfoxide was used to dissolve the insoluble formazan in a colored
solution, quantified by a spectrophotometer at 595 nm (GloMax®-Multi+ Microplate Multimode
Reader, Promega Corporation, Madison, WI, USA). The absorbance values are directly proportional to
the number of viable cells and normalized to the untreated condition.
2.4. Analysis of Impedance with xCELLigence System
The xCELLigence RTCA DP Instrument (Roche, Penzberg, Germany) was used to assess number,
viability, and morphology of the cultured cells. The xCELLigence RTCA system is a label-free approach
that uses the electrical impedance of the adherent cells, expressed as a cell index (CI) value, to monitor
the biological status of cells. With this instrument, any change in cellular morphology or growth rate
that leads to detachment or death of cultured cells (for example the addition of toxic compounds)
determines a reduction of the CI.
For this analysis, 2.5 × 104 HT29 cells per well were seeded in a 16-well plate (E-plate; Roche)
in 200 µL of complete medium, and cultured at 37 ◦C in 5% CO2. The cells were stimulated with
IFNγ, with a curcumin 24-h pre-incubation. The impedance values were automatically measured
every 15 min for 96 h. This assay was repeated twice in triplicate. The CI curves were normalized at
the addition of IFNγ to compare more precisely the effect of the tested treatment. Ninety-six hours
after seeding, CI was also normalized to the untreated control.
2.5. NF-kB Signaling Assay
The MILLIPLEX® MAP 6-plex magnetic bead signaling kit (EMD Millipore Corporation, Billerica,
MA, USA), was used to detect changes in phosphorylated NF-κB (Ser536), FADD (Ser194), IKKα/β
(Ser177/Ser181), IκBα (Ser32) and in total protein levels of TNFR1 and c-Myc, in HT29 cell lysates.
Briefly, cells were seeded in a 12-well plate at a cell density of 3.3 × 105 per well, pre-incubated or not
with curcumin, and then stimulated with IFNγ. Forty-eight hours after stimulation cell were harvested,
washed with phosphate-buffered saline and lysed in the provided lysis buffer supplemented with
protease inhibitors. To remove particulate matter, lysates were centrifuged at 14,000× g for 20 min at
4 ◦C. Cell lysates were analyzed following manufacturer’s instructions using the Luminex technology.
Samples were acquired with the Bio-Plex® 200 reader (BioRad, Hemel Hempstead, UK) and data were
analyzed by Bio-Plex Manager® software, which returned data as median fluorescence intensities
(MFI). Results were represented as means and standard deviations of four replicate wells.
2.6. Cytokine Quantifications
Cytokines and chemokines released in the culture medium were quantified using the Bio-Plex
Pro® Human Cytokine 17-plex Assay, according to the manufacturer’s instructions (BioRad). Briefly,
for the cytokine analysis, cells were seeded in a 12-well plate at a cell density of 3.3 × 105 per well.
Forty-eight hours after seeding, cells were pre-incubated or not with curcumin and then stimulated
with 100 U/mL IFNγ. The cell supernatants were collected forty-eight hours after IFNγ treatment.
Analytes examined by this method were Interleukin (IL)1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12
(p70), IL13, IL17, granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage-colony
stimulating factor (GM-CSF), interferon (IFN)γ, monocyte chemotactic and activating factor (MCP1;
MCAF), macrophage inflammatory protein (MIP)1β, and Tumor necrosis factor (TNF)α. Data were
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acquired with a Bio-Plex® 200 reader (BioRad), using Bio-Plex Manager® software, which returned
data as median fluorescence intensities (MFI) and concentrations (pg/mL).
2.7. Data Analysis
All results are expressed as means± standard deviation (SD). Statistical significance was calculated
using one-way analysis of variance (ANOVA) and Bonferroni post-test. Statistical significance was set
at p < 0.05 (a), p < 0.01 (b), and p < 0.001 (c). Analyses were carried out using GraphPad Prism software
(version 5.0, GraphPad Software Inc., La Jolla, CA, USA).
3. Results
3.1. Time-Dependent Modulation of Apoptosis by Curcumin Pre-Treatment
Apoptosis rate of HT29 was assessed by the Annexin V-FITC (An) Apoptosis Detection Kit.
As expected, treatment with IFNγ alone led to a significantly increased cell apoptosis (1.749-fold more
An-positive cells compared with the unstimulated control, p < 0.001; Figure 2). Cultures pre-incubated
with curcumin had a lower fraction of apoptotic cells compared to non-pre-treated cell cultures, with
a trend of higher preventive effect at longer pre-incubation times. Indeed, the preventive effect was
particularly evident, albeit not complete, when curcumin pretreatment was started 24 h before the
addition of IFNγ (IFNγ: 1.749 vs. Cur-24h + IFNγ: 1.348; p < 0.05). This beneficial effect gradually
declined with the reduction of the pre-incubation period. Curcumin, alone (administered 24 h before
the inflammatory stimulus), did not perturb the cell viability (Figures 2 and 3).
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Figure 4. Viability analysis on HT29 pre-stimulated with curcumin. HT29 cell line was pre-incubated
with curcumin (Cur) and after 24 h stimulated with IFNγ for an additional 48 h, to evaluate cell viability
through MTT assay. Results are expressed as means ± SD, in percentage (%), normalized to the control
condition (Untr). Data were analyzed ith o e-way ANOVA using the Bonferroni post-test (a: p < 0.05;
b: p < 0.01).
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3.3. Curcumin Effect on the Impedance Profile
The impedance measurement has confirmed the toxic effect of the IFNγ on cell status and the
protective action of the curcumin administered 24 h before the addition of IFNγ. The representative
xCELLigence graph (Figure 5) showed that the IFNγ addition led to a slight decrease in CI values
(blue line), and the pre-treatment with curcumin stabilized the course of the line (pink line) up to the
untreated condition (red line). Curcumin, alone, induced an increase of the impedance profile, possibly
due to a change in cell morphology or adhesion strength (green line). Reporting the average of the
normalized CI values obtained by different experiments after about 96 h of cell culture, it was possible
to highlight that these differences are significant (Untr: 99.67 ± 26.84 vs. IFNγ 54.50 ± 14.39, p < 0.05;
Cur-24h + IFNγ: 101.0 ± 18.40, p < 0.05; Figure 6).
Nutrients 2017, 9, 578 7 of 12 
 
xCELLigence graph (Figure 5) showed that the IFNγ addition led to a slight decrease in CI values 
(blue line), and the pre-treatment with curcumin stabilized the course of the line (pink line) up to the 
untreated condition (red line). Curcumin, alone, induced an increase of the impedance profile, 
possibly due to a change in cell morphology or adhesion strength (green line). Reporting the average 
of the normalized CI values obtained by different experiments after about 96 h of cell culture, it was 
possible to highlight that these differences are significant (Untr: 99.67 ± 26.84 vs. IFNγ 54.50 ± 14.39, 
p < 0.05; Cur-24h + IFNγ: 101.0 ± 18.40, p < 0.05; Figure 6).  
 
Figure 5. Representative impedance profile after curcumin pre-treatment. HT29 cells, cultured in a 
16-well E-plate, were pre-treated with curcumin (Cur, 24 h after seeding), and stimulated with IFNγ 
(48 h after seeding) for a further 48 h. The graph shows the cell index values, normalized at the time 
of the IFNγ stimulation. The experiment was performed in triplicate. 
 
Figure 6. Impedance analysis of HT29 pre-treated with curcumin. The HT29 cells were pre-treated 
with curcumin (Cur, 24 h after seeding), and stimulated with IFNγ (48 h after seeding). The 
histograms represent, as a percentage (%), the mean of the normalized cell index values, reached after 
about 48 h IFNγ stimulation, compared to the untreated condition (Untr). Data are expressed as the 
mean ± SD. Data analyses were performed with one-way ANOVA and the Bonferroni post-test (a: p 
< 0.05). 
3.4. Absence of NF-κB Modulation by Curcumin Pre-Treatment 
IFNγ, as an inflammatory stimulus, was capable of activating the NF-κB (nuclear factor kappa 
B) pathway, as evidenced by the increased level of phosphoprotein of this signaling cascade, such as 
the transcription factor NF-κB and the upstream factors, IκBα and IKKα/β (NF-κB: 136.4 ± 23.39 vs. 
314.5 ± 52.14 p < 0.001; IKKα/β: 43.20 ± 15.79 vs. 105.0 ± 29.60 p < 0.01; IκBα: 274.8 ± 45.38 vs. 453.7 ± 
116 p < 0.01). The pre-treatment with curcumin lowered the levels of these phosphorylated analytes 
slightly, but these trends were not significant (Figure 7). The other proteins analyzed (FADD, TNFR1, 
and c-Myc) did not show any significant differences after the inflammatory and curcumin treatment 
(data not shown). 
Figure 5. Representative impedance profile after curcumin pre-treatment. HT29 cells, cultured in a
16-well E-plate, were pre-treated with curcumin (Cur, 24 h after seeding), and stimulated with IFNγ
(48 h after seeding) for a further 48 h. The graph shows the cell index values, normalized at the time of
the IFNγ stimulation. The experiment was performed in triplicate.
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Figure 6. Impedance analysis of HT29 pre-treated with curcumin. The HT29 cells ere pre-treated
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represent, as a percentage (%), the mean of the normalized cell index values, reached after about 48 h
IFNγ stimulation, compared to the untreated condition (Untr). Data are expressed as the mean ± SD.
Data analyses were performed with one-way ANOVA and the Bonferroni post-test (a: p < 0.05).
3.4. Absence of NF-κB Modulation by Curcumin Pre-Treatment
IFNγ, as an inflammatory stimulus, was capable of activating the NF-κB (nuclear factor kappa
B) pathway, as evidenced by the increased level of phosphoprotein of this signaling cascade, such
as the transcription factor NF-κB and the upstrea factors, IκBα and IKKα/β (NF-κB: 136.4 ± 23.39
vs. 314.5 52.14 p < 0.001; I Kα/β: 43.20 ± 15.79 vs. 105.0 ± 29.60 p < 0.01; IκBα: 274.8 ± 45.38 vs.
453.7 ± 116 p < 0.01). The pre-treatment with curcumin low r d the lev ls of these phosphorylat d
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analytes slightly, but these trends were not significant (Figure 7). The other proteins analyzed (FADD,
TNFR1, and c-Myc) did not show any significant differences after the inflammatory and curcumin
treatment (data not shown).
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HT29 cells. HT29 cells were pre-treated with curcumin (Cur) and then, after 24 h, stimulated with
IFNγ for a further 48 h to detect changes in phosphorylated proteins belonging to the NF-κB pathway
(NF-κB, IKKα/β, and IκBα), using a magnetic bead signaling kit and a Bio-Plex multiplex reader. Data,
expressed as the median fluorescence intensity (MFI), represent the mean ± SD of four replicates and
were analyzed with one-way ANOVA using the Bonferroni post-test (b: p < 0.01; c: p < 0.001).
3.5. Downregulation f the IL7 Secretion by Curcumin
The IFNγ treatment ind an increase of IL7 release in the HT29 culture media (Untr:
21.51 ± 2 40 vs. IFNγ: 88.76 ± 15. p < 0.001, Figure 8). When administered 24 h before the
inflam atory stimulus, curcumin led to a significant downregulation of the levels of ytokines secreted,
compared with the values obtained after the administration of I alone (IFNγ: 88.76 ± 15.01 vs.
Cur-24h + IFNγ: 54.54 ± 5.25, p < 0.01, Figure 8). With respect to the other analytes, no significant and
biological differences were found between the four analyzed conditions (data not shown).
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curcumin (Cur) and, after 24 h, stim lated with IFNγ for an additional 48 h to evaluate the cytokine
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four replicates. Data were analyzed with one-way ANOVA using the Bonferroni post-test; (b: p < 0.01;
c: p < 0.001).
4. Discussion
Cu cumin, the active substance of Curcum l a which is attributed most of the beneficial
properties of turmeric, is chemically classified among the polyphenols.
The many beneficial properties attributed to curcumin, as antioxidant, anti-inflammatory,
anti-infective, anti-tumor, and preventive agent, are closely correlated with each other and could
be associated with the ability to modulate the molecules involved in inflammation, programmed cell
death, and morphology.
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In the present work, we demonstrated that pre-treatment with curcumin is able to reduce the
levels of apoptosis in intestinal epithelial cells exposed to IFNγ. The fact that concordant data were
obtained with different methods strengthens the interpretation of the results. In particular, there was a
recent warning about the possibility that much of the research data on curcumin may be weakened, or
even invalidated, when natural properties of fluorescence and protein binding of the compound are
taken into account [25]. The inclusion in our research plan of a label-free assay based on cell impedance
analysis allows ruling out such interferences.
When we further investigated the protective mechanisms of action of curcumin on HT29 cells,
we observed that pre-treatment with this compound led to a significant reduction in the amount of
IL7 secreted in response to IFNγ. IL7 is a crucial cytokine, usually secreted by intestinal epithelial
cells in response to bacterial infections, which contributes to the organization of secondary lymphoid
structures [28,29]. While basal secretion of this cytokine in response to the intestinal microbiota may
be required for an optimal homeostasis of the mucosal immunity [30,31], higher levels may play a role
in the pathogenesis of IBD and inhibition of IL7 has been proposed as a complementary approach
to target inflammation in these disorders [32–35]. Since mucosal production of IL7 in vivo has been
implicated in the activation of pathogenic CD4 T lymphocytes, the action of curcumin on this cytokine
may be independently useful to contrast intestinal inflammation [36,37].
Although a cell line cultured in the laboratory can hardly reflect the complex physiology of
intestinal mucosa, HT29 cells are considered a good model to study cytokine-induced apoptosis in
epithelial cells. The model is coherent with in vivo data showing that epithelial apoptosis is increased
in intestinal mucosa in subjects with the active disease while it is reversed by anti-inflammatory
treatment with anti-TNFα antibodies. Increased apoptosis in epithelial cells is thought to contribute to
increased permeability and amplification of inflammation. Thus, inhibiting inflammation-induced
epithelial cell apoptosis may be relevant to the prevention or the treatment of IBD, as suggested by
recent data [10].
It is not clear how curcumin acts on IFNγ-induced apoptosis and cytokine secretion. One of
the known actions of curcumin regards iron chelation and reduction [38–41], but it is not clear if the
anti-inflammatory and anti-apoptotic effects of the drug may depend on this property. We evaluated
NF-κB activation since this pathway is a known target of IFNγ. Even if there was a trend toward
reduction of the levels of phosphorylated components of NF-κB, this did not reach statistical
significance. Thus, we could not conclude that the downregulation of the NF-κB pathway is the
main mechanism of action of curcumin. A possible alternative explanation is that curcumin exerts its
anti-inflammatory property by a direct modulation of mitochondrial function, as suggested by other
authors [42].
Although we must put much caution in translating data obtained in vitro on a cell line, we can
hypothesize that our results may be relevant to the understanding of the action of curcumin in vivo.
In particular, a protective effect of curcumin was described in a mouse model of UC [43]. Moreover,
small clinical trials in UC seem to suggest that curcumin may be a promising and safe complementary
medication for maintaining remission in patients with quiescent disease [44].
An issue that should be addressed to assess the real potential of curcumin into the clinic concerns
its poor aqueous solubility and low bioavailability, which may hinder in vivo efficacy [45]; low
plasma levels and limited tissue distribution of curcumin appear to be due to poor absorption,
high-rate metabolism, and rapid systemic clearance. A possible solution to these issues would be
the development of different types of curcumin formulations, such as nanoparticles, liposomes, or
phospholipid complexes, which increase and improve not only its stability, but also its biodistribution
and absorption [46]. With these new strategies, an enhanced bioavailability and efficacy have been
documented in different experimental models. Therefore, further exploration to increase the medical
value for human applications are needed.
Our study was carried out on a single cell-type model. Even if preliminary studies in animals
and patients are promising and coherent with our data, we should consider the possibility that similar
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results cannot be obtained in vivo. Moreover, since we used ultra-pure curcumin, we should warn
about the risk of translating our results to commercially-available preparations of curcuma, which may
contain several other compounds with contrasting effects on mucosal immunity [47].
5. Conclusions
Despite being encouraging, our results need further and deeper investigations aimed at
establishing whether curcumin could be a potential therapeutic molecule for IBD and, in particular,
for UC.
In conclusion, even though our results are preliminary and need to be verified in order to be
translated into the model of IBD patients, they should be considered as a first step to better characterize
turmeric anti-inflammatory properties.
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